New & Notable
Trust concerns hinder agentic AI adoption, orchestration
Despite significant investment, most pharmaceutical and life sciences companies are struggling to bring agentic AI into production, a new report says.
Nvidia partners with Lilly to launch $1B AI drug discovery lab
Nvidia and Eli Lilly team up to invest $1 billion in a new AI lab to speed up drug discovery using Nvidia's BioNeMo platform and its next-gen Vera Rubin architecture.
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
Healthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Lilly's triple agonist led to high weight loss, reduced knee pain
Eli Lilly's 'triple-G' agonist led to an average weight loss of up to 28.7% and knee pain relief in a late-phase trial, but caused a rare, neurological side effect in some patients.
-
Structure announces mid-stage data for its oral GLP-1 candidate
Structure Therapeutics reported a placebo-adjusted weight loss of up to 15.3% for its oral GLP-1 drug candidate, aleniglipron, in a high-dose, exploratory phase 2 analysis.
-
Ascletis announces phase 2 data for its oral GLP-1 candidate
China's Ascletis Pharma reported a 7.7% placebo-adjusted weight loss for the highest dose of its oral GLP-1 drug candidate, ASC30, in a U.S.-based, phase 2 trial.
-
Eli Lilly lowers Zepbound costs amid rising calls for affordability
Lilly cuts prices for its weight loss drug Zepbound as the World Health Organization issues its first global GLP-1 obesity guidelines, urging expanded access and affordability.
-
WHO releases its first-ever GLP-1 weight-loss drug guidelines
GLP-1 drugs approved for weight loss can be combined with behavioral therapy as part of a long-term strategy in adults, the WHO says in new guidance.
-
Novo Nordisk's amycretin shows competitive phase 2 weight loss
After yesterday's setback, Novo Nordisk released mid-stage data showing oral and injectable amycretin led to 7.6% and 11.9% placebo-adjusted weight loss, respectively, in patients with type 2 diabetes.
Features
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.
-
Expanding clinical trial access through technology, support
Systemic barriers continue to restrict clinical trial access, but when deployed correctly, technology can provide patient–provider support and close interoperability gaps.
-
Will the FDA's green list end illegal GLP-1 compounding?
The FDA recently created a green list to regulate imported GLP-1 drug ingredients, yet experts say that weak enforcement could allow illegal compounding operations to continue.
-
Using AI to identify, expose online drug counterfeiters
Pharmaceutical companies are leveraging AI's advanced detection and enforcement tools to combat the online counterfeit drug market, protecting brand integrity and consumer safety.